dr. mirza on the rationale for the avanova trial in recurrent ovarian cancer
Published 5 years ago • 194 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
0:49
dr. mirza on the engot-ov42-nsgo/avanova-triplet trial in recurrent ovarian cancer
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
1:35
dr. mirza on the phase iii nova trial in ovarian cancer
-
2:18
dr. mirza on final data of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
0:56
dr. mirza on the implications of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
5:13
treating ovarian cancer with niraparib: the nova trial
-
1:41
dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
-
1:30
dr. mirza on niraparib efficacy across ovarian cancer subgroups
-
0:57
dr. mirza on impact of niraparib in ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
3:11
the avanova study: niraparib and bevacizumab for ovarian cancer
-
1:20
dr. ledermann on rationale for ariel3 trial in ovarian cancer
-
6:57
niraparib maintenance for recurrent ovarian cancer
-
8:29
esmo 2019: dr. mirza on important trials with parp inhibitors in ovarian cancer
-
6:04
when to add bevacizumab for recurrent ovarian cancer
-
1:25
dr. matulonis on final data from keynote-100 in recurrent ovarian cancer
-
1:47
dr. matulonis on the nova trial of niraparib maintenance therapy in ovarian cancer